Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238466 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
A Phase 1 study of Cardiovascular, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 5
- Study locations
NCT06238466: Active Phase 1 study of Cardiovascular, sponsored by AstraZeneca.
NCT06238466 is a Phase 1 study of Cardiovascular that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 96 participants, below the 242-participant average among 8 other Cardiovascular trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238466, a Phase 1 study of Cardiovascular, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 5
- Study locations
Study Summary
A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
Primary Outcome
To assess the safety and tolerability of AZD1705 following subcutaneous administration of single ascending doses (Part A) and multiple ascending doses (Part B) in participants with dyslipidemia
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD1705
Study Locations (5)
Florida
- Research Site - Jacksonville
- Research Site - Winter Park
California
- Research Site - Glendale
Maryland
- Research Site - Baltimore
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
What the registry record for NCT06238466 still lists
NCT06238466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 242-participant average among 8 other Cardiovascular trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Cardiovascular appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06238466 lists 5 locations in 4 states (Florida, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT06238466 about?
NCT06238466 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia". A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
What is the current status of trial NCT06238466?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-01-16. Estimated completion is 2026-08-31.
What conditions does trial NCT06238466 study?
This clinical trial studies the following conditions: Cardiovascular.
What interventions are being tested in trial NCT06238466?
The interventions under investigation include: Placebo (OTHER), AZD1705 (DRUG).
Who is sponsoring clinical trial NCT06238466?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238466 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06238466's enrollment target sits among peer trials
96 6th of 8 higher than 3 of 8 other Cardiovascular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Decoupling Immunotherapy Toxicity and Cancer Response
RECRUITING
-
Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury
RECRUITING · NA
-
AI Platform for Fatigue and Depression Detection
RECRUITING
-
Improving the Heart Health of Home Health Aides
RECRUITING · NA
-
Adequate Hydration and Health Outcomes
RECRUITING · NA
-
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI